Cancer Channel
Related Channels

Panitumumab Side Effects

Common Side Effects

Panitumumab has been studied extensively in clinical trials. In these studies, the side effects that occurred in a group of people who received panitumumab were carefully documented and compared to the side effects that occurred in a similar group of people who did not receive panitumumab. As a result, it was possible to see what side effects occurred and how often they appeared.
In these studies, the most common panitumumab side effects included:
  • Skin reactions -- in up to 90 percent of people
  • Low blood magnesium levels (hypomagnesemia) -- up to 38 percent
  • Fatigue -- up to 26 percent
  • Infections around the toenails and fingernails -- up to 25 percent
  • Abdominal (stomach) pain -- up to 25 percent
  • Nausea -- up to 23 percent
  • Diarrhea -- up to 21 percent
  • Constipation -- up to 21 percent
  • Vomiting -- up to 19 percent.
Other common side effects, occurring in 3 percent to 15 percent of people, included but were not limited to:
  • Eye problems, such as:
    • Inflammation
    • Redness
    • Tearing
    • Irritation
  • Cough
  • Swelling of the arms, hands, legs, ankles, and feet
  • Sores and inflammation of the mouth
  • Problems with the toenails or fingernails
  • Growth of hair and eyelashes
  • Reactions to the infusion.
The majority of people in clinical trials experienced a skin reaction of some type, usually within the first two weeks of starting treatment. Reported reactions included:
  • Redness
  • An acne-like rash
  • Other rashes
  • Itching
  • Peeling skin
  • Cracking skin
  • Dry skin.
5 Easy Tips to Manage Visitors During Cancer Treatment

Panitumumab Drug Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.